Fulminant toxic epidermal necrolysis induced by pucotenlimab in a patient with lung adenocarcinoma: a case report.

Authors

Zhen Zhang, Qiqi Tao, Jing Wang, Jun Lu, Yue Ning

Published in

Frontiers in oncology. Volume 16. Pages 1790323. Epub Jun 26, 2026.

Abstract

This case report describes a fatal case of toxic epidermal necrolysis (TEN) in a 67-year-old man with stage IIIB lung adenocarcinoma (T₄N₂M₀), which developed 7 days after a single dose of pucotenlimab, a novel programmed death-1 (PD-1) inhibitor. The full course of thoracic radiotherapy was completed prior to immunotherapy initiation, and no persistent hypersensitivity reactions were documented despite concomitant antibiotic administration throughout this period. The patient presented with scattered erythematous papules that rapidly progressed to extensive epidermal detachment involving approximately 80% of the total body surface area (BSA). A baseline SCORTEN score of 6 calculated within 24 hours of readmission (Table 1) indicated a predicted mortality >90%, and the Naranjo Scale yielded a score of 6 (Table 2), confirming a probable causal association between TEN and pucotenlimab. Acute-phase immunological profiling revealed markedly reduced PD-1 expression on circulating T cells and significantly elevated interleukin-6 (IL-6), providing exploratory evidence for aberrant T-cell activation as a potential pathogenic mechanism. Despite intensive multidisciplinary management with systemic corticosteroids, intravenous immunoglobulin (IVIG) and supportive care, the patient's condition progressively deteriorated. After written informed consent for withdrawal of life-sustaining treatment was obtained from the patient's legal next of kin, the patient was discharged on July 31 and succumbed to his illness shortly thereafter. This case highlights the fatal risk of rare severe cutaneous immune-related adverse events (irAEs) associated with PD-1 inhibitors. It also emphasizes the importance of early recognition, prompt discontinuation of further PD-1 inhibitor administration, and timely combination therapy with corticosteroids and etanercept to improve outcomes in high-risk patients.

PMID:
42434740
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.